Roles of noncoding RNAs in drug resistance in multiple myeloma.
drug resistance
long noncoding RNA
microRNA
multiple myeloma
signaling pathway
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
29
10
2019
revised:
08
04
2020
accepted:
10
04
2020
pubmed:
24
4
2020
medline:
9
3
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
Despite the administration of new effective drugs in recent years, relapse and drug resistance are still the main obstacles in multiple myeloma (MM) treatment, making MM an incurable disease. To overcome drug resistance in MM, it is critical to understand the underlying mechanisms of malfunctioning gene expression and develop novel targeted therapies. During the past few decades, with the discovery and characterization of noncoding RNAs (ncRNAs), the landscape of dysregulated ncRNAs of cancers as well as their biological and pathobiological functions in tumorigenesis and drug resistance have been recognized. Studies about ncRNAs improved the understanding of variations of drug response among individuals at a level distinguished from genetic polymorphism, and provided with new orientations for targeted therapies. In this review, we will summarize the emerging impact and underlying molecular mechanisms of the most relevant classes of ncRNAs in drug resistance of MM, and discuss the potential as well as strategies of treating ncRNAs as therapeutic targets.
Substances chimiques
RNA, Untranslated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7681-7695Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Alzrigat, M., Parraga, A. A., Agarwal, P., Zureigat, H., Osterborg, A., Nahi, H., & Jernberg-Wiklund, H. (2017). EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget, 8(6), 10213-10224. https://doi.org/10.18632/oncotarget.14378
Amodio, N., Di Martino, M. T., Foresta, U., Leone, E., Lionetti, M., Leotta, M., & Tassone, P. (2012). miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death & Disease, 3(11), e436. https://doi.org/10.1038/cddis.2012.175
Amodio, N., Stamato, M. A., Gulla, A. M., Morelli, E., Romeo, E., Raimondi, L., & Tassone, P. (2016). Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Molecular Cancer Therapeutics, 15(6), 1364-1375. https://doi.org/10.1158/1535-7163.Mct-15-0985
Amodio, N., Stamato, M. A., Juli, G., Morelli, E., Fulciniti, M., Manzoni, M., & Tassone, P. (2018). Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia, 32(9), 1948-1957. https://doi.org/10.1038/s41375-018-0067-3
Ballabio, E., Armesto, M., Breeze, C. E., Manterola, L., Arestin, M., Tramonti, D., & Lawrie, C. H. (2012). Bortezomib action in multiple myeloma: MicroRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?Blood Cancer Journal, 2(8), e83. https://doi.org/10.1038/bcj.2012.31
Barrett, S. P., Wang, P. L., & Salzman, J. (2015). Circular RNA biogenesis can proceed through an exon-containing lariat precursor. eLife, 4, e07540. https://doi.org/10.7554/eLife.07540
Benetatos, L., Dasoula, A., Hatzimichael, E., Georgiou, I., Syrrou, M., & Bourantas, K. L. (2008). Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clinical Lymphoma & Myeloma, 8(3), 171-175. https://doi.org/10.3816/CLM.2008.n.021
Bergsagel, P. L., & Kuehl, W. M. (2005). Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology, 23(26), 6333-6338. https://doi.org/10.1200/jco.2005.05.021
Binder, S., Hösler, N., Riedel, D., Zipfel, I., Buschmann, T., Kämpf, C., & Horn, F. (2017). STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer. Scientific Reports, 7(1), 7976. https://doi.org/10.1038/s41598-017-08348-5
Cech, T. R., & Steitz, J. A. (2014). The noncoding RNA revolution-trashing old rules to forge new ones. Cell, 157(1), 77-94. https://doi.org/10.1016/j.cell.2014.03.008
Chen, L. L. (2016). The biogenesis and emerging roles of circular RNAs. Nature Reviews Molecular Cell Biology, 17(4), 205-211. https://doi.org/10.1038/nrm.2015.32
Cheng, D. L., Xiang, Y. Y., Ji, L. J., & Lu, X. J. (2015). Competing endogenous RNA interplay in cancer: Mechanism, methodology, and perspectives. Tumour Biology, 36(2), 479-488. https://doi.org/10.1007/s13277-015-3093-z
Cheng, Q., Li, X., Liu, J., Ye, Q., Chen, Y., Tan, S., & Liu, J. (2017). Multiple myeloma-derived exosomes regulate the functions of mesenchymal stem cells partially via modulating miR-21 and miR-146a. Stem Cells International, 2017, 9012152. https://doi.org/10.1155/2017/9012152
Cho, S. F., Chang, Y. C., Chang, C. S., Lin, S. F., Liu, Y. C., Hsiao, H. H., & Liu, T. C. (2014). MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer, 14, 809. https://doi.org/10.1186/1471-2407-14-809
Corrado, C., Costa, V., Giavaresi, G., Calabrese, A., Conigliaro, A., & Alessandro, R. (2019). Long non coding RNA H19: A new player in hypoxia-induced multiple myeloma cell dissemination. International Journal of Molecular Sciences, 20(4), 801. https://doi.org/10.3390/ijms20040801
Corthals, S. L., Jongen-Lavrencic, M., de Knegt, Y., Peeters, J. K., Beverloo, H. B., Lokhorst, H. M., & Sonneveld, P. (2010). Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leukemia Research, 34(5), 677-681. https://doi.org/10.1016/j.leukres.2009.10.026
Dahl, M., Daugaard, I., Andersen, M. S., Hansen, T. B., Grønbaek, K., Kjems, J., & Kristensen, L. S. (2018). Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Laboratory Investigation, 98(12), 1657-1669. https://doi.org/10.1038/s41374-018-0108-6
deLarrea, C. F., Navarro, A., Tejero, R., Tovar, N., Diaz, T., Cibeira, M. T., & Blade, J. (2012). Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 18(13), 3697-3704. https://doi.org/10.1158/1078-0432.Ccr-12-0191
Debes-Marun, C. S., Dewald, G. W., Bryant, S., Picken, E., Santana-Davila, R., Gonzalez-Paz, N., & Fonseca, R. (2003). Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 17(2), 427-436. https://doi.org/10.1038/sj.leu.2402797
Derksen, P. W., Tjin, E., Meijer, H. P., Klok, M. D., Mac Gillavry, H. D., vanOers, M. H., & Pals, S. T. (2004). Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 101(16), 6122-6127. https://doi.org/10.1073/pnas.0305855101
Di Martino, M. T., Leone, E., Amodio, N., Foresta, U., Lionetti, M., Pitari, M. R., & Tassone, P. (2012). Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 18(22), 6260-6270. https://doi.org/10.1158/1078-0432.Ccr-12-1708
Diederichs, S., Bartsch, L., Berkmann, J. C., Frose, K., Heitmann, J., Hoppe, C., & Wullenkord, R. (2016). The dark matter of the cancer genome: Aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Molecular Medicine, 8(5), 442-457. https://doi.org/10.15252/emmm.201506055
Du, J., Liu, S., He, J., Liu, X., Qu, Y., Yan, W., & Hou, J. (2015). MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget, 6(17), 14993-15007. https://doi.org/10.18632/oncotarget.3802
Feng, D. D., Zhang, H., Zhang, P., Zheng, Y. S., Zhang, X. J., Han, B. W., & Chen, Y. Q. (2011). Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. Journal of Cellular and Molecular Medicine, 15(10), 2164-2175. https://doi.org/10.1111/j.1582-4934.2010.01213.x
Feng, Y., Zhang, L., Wu, J., Khadka, B., Fang, Z., Gu, J., & Liu, J. (2019). CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. Journal of Experimental & Clinical Cancer Research, 38(1), 54. https://doi.org/10.1186/s13046-019-1071-9
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., & Avet-Loiseau, H. (2004). Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Research, 64(4), 1546-1558.
Fu, Y., Liu, X., Zhang, F., Jiang, S., Liu, J., & Luo, Y. (2019). Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b. Cell Death & Disease, 10(4), 319. https://doi.org/10.1038/s41419-019-1551-z
Gao, D., Lv, A. E., Li, H. P., Han, D. H., & Zhang, Y. P. (2017). LncRNA MALAT-1 elevates HMGB1 to promote autophagy resulting in inhibition of tumor cell apoptosis in multiple myeloma. Journal of Cellular Biochemistry, 118(10), 3341-3348. https://doi.org/10.1002/jcb.25987
Gao, M., Li, C., Xiao, H., Dong, H., Jiang, S., Fu, Y., & Gong, L. (2019). hsa_circ_0007841: A novel potential biomarker and drug resistance for multiple myeloma. Frontiers in Oncology, 9, 1261. https://doi.org/10.3389/fonc.2019.01261
Geng, W., Guo, X., Zhang, L., Ma, Y., Wang, L., Liu, Z., & Xiong, Y. (2018). Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/beta-catenin signaling pathway. Biomedicine & Pharmacotherapy = Biomédecine & pharmacothérapie, 107, 484-494. https://doi.org/10.1016/j.biopha.2018.08.003
Greco, C., D'Agnano, I., Vitelli, G., Vona, R., Marino, M., Mottolese, M., & Ameglio, F. (2006). c-MYC deregulation is involved in melphalan resistance of multiple myeloma: Role of PDGF-BB. International Journal of Immunopathology and Pharmacology, 19(1), 67-79.
Greenstein, S., Ghias, K., Krett, N. L., & Rosen, S. T. (2002). Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 8(6), 1681-1694.
Gu, Y., Xiao, X., & Yang, S. (2017). LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression. Oncotarget, 8(60), 101984-101993. https://doi.org/10.18632/oncotarget.21957
Guan, R., Wang, W., Fu, B., Pang, Y., Lou, Y., & Li, H. (2019). Increased lncRNA HOTAIR expression promotes the chemoresistance of multiple myeloma to dexamethasone by regulating cell viability and apoptosis by mediating the JAK2/STAT3 signaling pathway. Molecular Medicine Reports, 20(4), 3917-3923. https://doi.org/10.3892/mmr.2019.10603
Gullà, A., Di Martino, M. T., Gallo Cantafio, M. E., Morelli, E., Amodio, N., Botta, C., & Tassone, P. (2016). A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22(5), 1222-1233. https://doi.org/10.1158/1078-0432.CCR-15-0489
Handa, H., Kuroda, Y., Kimura, K., Masuda, Y., Hattori, H., Alkebsi, L., & Murakami, H. (2017). Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. British Journal of Haematology, 179(3), 449-460. https://doi.org/10.1111/bjh.14882
Hao, M., Zhang, L., An, G., Meng, H., Han, Y., Xie, Z., & Qiu, L. (2011). Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leukemia and Lymphoma, 52(9), 1787-1794. https://doi.org/10.3109/10428194.2011.576791
Hao, M., Zhang, L., An, G., Sui, W., Yu, Z., Zou, D., & Qiu, L. (2011). Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. Journal of Hematology & Oncology, 4, 37. https://doi.org/10.1186/1756-8722-4-37
Hazlehurst, L. A., & Dalton, W. S. (2001). Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer and Metastasis Reviews, 20(1-2), 43-50.
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 7(8), 585-598. https://doi.org/10.1038/nrc2189
Hu, Y., Lin, J., Fang, H., Fang, J., Li, C., Chen, W., & Zhao, J.-J. (2018). Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia, 32(10), 2250-2262. https://doi.org/10.1038/s41375-018-0104-2
Huang, X., Yang, M., & Jin, J. (2012). Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs. Leukemia and Lymphoma, 53(6), 1188-1195. https://doi.org/10.3109/10428194.2011.638069
Jagannathan, S., Vad, N., Vallabhapurapu, S., Vallabhapurapu, S., Anderson, K. C., & Driscoll, J. J. (2015). MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia, 29(3), 727-738. https://doi.org/10.1038/leu.2014.279
Joao, C., Costa, C., Coelho, I., Vergueiro, M. J., Ferreira, M., & daSilva, M. G. (2014). Long-term survival in multiple myeloma. Clinical Case Reports, 2(5), 173-179. https://doi.org/10.1002/ccr3.76
Jovanovic, K. K., Roche-Lestienne, C., Ghobrial, I. M., Facon, T., Quesnel, B., & Manier, S. (2018). Targeting MYC in multiple myeloma. Leukemia, 32(6), 1295-1306. https://doi.org/10.1038/s41375-018-0036-x
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004). The IKK NF-kappa B system: A treasure trove for drug development. Nature Reviews. Drug discovery, 3(1), 17-26. https://doi.org/10.1038/nrd1279
Kole, R., Krainer, A. R., & Altman, S. (2012). RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nature Reviews. Drug Discovery, 11(2), 125-140. https://doi.org/10.1038/nrd3625
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., & Pogribny, I. P. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Molecular Cancer Therapeutics, 7(7), 2152-2159. https://doi.org/10.1158/1535-7163.Mct-08-0021
Kristensen, L. S., Hansen, T. B., Venø, M. T., & Kjems, J. (2018). Circular RNAs in cancer: Opportunities and challenges in the field. Oncogene, 37(5), 555-565. https://doi.org/10.1038/onc.2017.361
Kugel, J. F., & Goodrich, J. A. (2012). Non-coding RNAs: Key regulators of mammalian transcription. Trends in Biochemical Sciences, 37(4), 144-151. https://doi.org/10.1016/j.tibs.2011.12.003
Le Gouill, S., Podar, K., Harousseau, J. L., & Anderson, K. C. (2004). Mcl-1 regulation and its role in multiple myeloma. Cell Cycle, 3(10), 1259-1262. https://doi.org/10.4161/cc.3.10.1196
Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gulla, A., & Tassone, P. (2013). Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(8), 2096-2106. https://doi.org/10.1158/1078-0432.Ccr-12-3325
Leotta, M., Biamonte, L., Raimondi, L., Ronchetti, D., Di Martino, M. T., Botta, C., & Amodio, N. (2014). A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. Journal of Cellular Physiology, 229(12), 2106-2116. https://doi.org/10.1002/jcp.24669
Li, F., Xu, Y., Deng, S., Li, Z., Zou, D., Yi, S., & Qiu, L. (2015). MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget, 6(35), 38270-38282. https://doi.org/10.18632/oncotarget.5681
Li, Y., Zhang, B., Li, W., Wang, L., Yan, Z., Li, H., & Li, Z. (2016). MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma. Leukemia Research, 49, 73-79. https://doi.org/10.1016/j.leukres.2016.08.013
Lin, J., Hu, Y., & Zhao, J. J. (2018). Repression of multiple myeloma cell growth in vivo by single-wall carbon nanotube (SWCNT)-delivered MALAT1 antisense oligos. Journal of Visualized Experiments: JoVE, (142), https://doi.org/10.3791/58598
Lionetti, M., Barbieri, M., Manzoni, M., Fabris, S., Bandini, C., Todoerti, K., & Neri, A. (2016). Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: An Italian cohort study and overview of the literature. Oncotarget, 7(16), 21353-21361. https://doi.org/10.18632/oncotarget.7241
Lionetti, M., Biasiolo, M., Agnelli, L., Todoerti, K., Mosca, L., Fabris, S., & Neri, A. (2009). Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood, 114(25), e20-e26. https://doi.org/10.1182/blood-2009-08-237495
Liu, D., Wang, J., & Liu, M. (2019). Long noncoding RNA TUG1 promotes proliferation and inhibits apoptosis in multiple myeloma by inhibiting miR-29b-3p. Bioscience Reports, 39(3), BSR20182489. https://doi.org/10.1042/BSR20182489
Liu, H., Wu, Y., Wang, S., Jiang, J., Zhang, C., Jiang, Y., & Huang, H. (2019). Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p. BMC Cancer, 19(1), 937. https://doi.org/10.1186/s12885-019-6088-0
Loffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermuller, J., Kretzschmar, A. K., & Horn, F. (2007). Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 110(4), 1330-1333. https://doi.org/10.1182/blood-2007-03-081133
Lu, D., Yang, C., Zhang, Z., Cong, Y., & Xiao, M. (2018). Knockdown of Linc00515 inhibits multiple myeloma autophagy and chemoresistance by upregulating miR-140-5p and downregulating ATG14. Cellular Physiology and Biochemistry, 48(6), 2517-2527. https://doi.org/10.1159/000492690
Ma, J., Gong, W., Liu, S., Li, Q., Guo, M., Wang, J., & Zhao, H. (2018). Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-kappaB and STAT3. Tumour Biology, 40(1):1010428317731369. https://doi.org/10.1177/1010428317731369
Manni, S., Carrino, M., Semenzato, G., & Piazza, F. (2018). Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance. International Journal of Molecular Sciences, 19(5), 1512. https://doi.org/10.3390/ijms19051512
Medh, R. D., Wang, A., Zhou, F., & Thompson, E. B. (2001). Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene, 20(34), 4629-4639. https://doi.org/10.1038/sj.onc.1204680
Min, D. J., Ezponda, T., Kim, M. K., Will, C. M., Martinez-Garcia, E., Popovic, R., & Licht, J. D. (2013). MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia, 27(3), 686-694. https://doi.org/10.1038/leu.2012.269
Misso, G., Zarone, M. R., Lombardi, A., Grimaldi, A., Cossu, A. M., Ferri, C., & Caraglia, M. (2019). miR-125b upregulates miR-34a and sequentially activates stress adaption and cell death mechanisms in multiple myeloma. Molecular Therapy Nucleic Acids, 16, 391-406. https://doi.org/10.1016/j.omtn.2019.02.023
Mithraprabhu, S., Kalff, A., Chow, A., Khong, T., & Spencer, A. (2014). Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics, 9(11), 1511-1520. https://doi.org/10.4161/15592294.2014.983367
Morelli, E., Leone, E., Cantafio, M. E., Di Martino, M. T., Amodio, N., Biamonte, L., & Tassone, P. (2015). Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia, 29(11), 2173-2183. https://doi.org/10.1038/leu.2015.124
Murray, M. Y., Rushworth, S. A., Zaitseva, L., Bowles, K. M., & Macewan, D. J. (2013). Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle, 12(13), 2144-2153. https://doi.org/10.4161/cc.25251
Nian, F., Zhu, J., & Chang, H. (2019). Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression. Biochemical and Biophysical Research Communications, 514(4), 1140-1146. https://doi.org/10.1016/j.bbrc.2019.05.078
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., vanZantwijk, I., Berkers, C. R., & Jansen, G. (2008). Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 112(6), 2489-2499. https://doi.org/10.1182/blood-2007-08-104950
Pan, Y., Chen, H., Shen, X., Wang, X., Ju, S., Lu, M., & Cong, H. (2018). Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Clinica Chimica Acta, 480, 199-205. https://doi.org/10.1016/j.cca.2018.02.019
Pan, Y., Zhang, Y., Liu, W., Huang, Y., Shen, X., Jing, R., & Chen, H. (2019). LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death & Disease, 10(2), 106. https://doi.org/10.1038/s41419-018-1219-0
Pang, J. C., Li, K. K., Lau, K. M., Ng, Y. L., Wong, J., Chung, N. Y., & Ng, H. K. (2010). KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathology, 20(6), 1021-1032. https://doi.org/10.1111/j.1750-3639.2010.00405.x
Poi, M. J., Li, J., Sborov, D. W., VanGundy, Z., Cho, Y. K., Lamprecht, M., & Hofmeister, C. C. (2017). Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis, 56(7), 1722-1732. https://doi.org/10.1002/mc.22626
Pollett, J. B., Trudel, S., Stern, D., Li, Z. H., & Stewart, A. K. (2002). Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood, 100(10), 3819-3821. https://doi.org/10.1182/blood-2002-02-0608
Qin, Y., Zhang, S., Deng, S., An, G., Qin, X., Li, F., & Qiu, L. (2017). Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia, 31(5), 1123-1135. https://doi.org/10.1038/leu.2016.325
Rajkumar, S. V. (2018). Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 93(8), 981-1114. https://doi.org/10.1002/ajh.25117
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018). Drug resistance in multiple myeloma. Cancer Treatment Reviews, 70, 199-208. https://doi.org/10.1016/j.ctrv.2018.09.001
Roccaro, A. M., Sacco, A., Thompson, B., Leleu, X., Azab, A. K., Azab, F., & Ghobrial, I. M. (2009). MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 113(26), 6669-6680. https://doi.org/10.1182/blood-2009-01-198408
Saha, M. N., Abdi, J., Yang, Y., & Chang, H. (2016). MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget, 7(6), 7149-7160. https://doi.org/10.18632/oncotarget.6880
Samur, M. K., Minvielle, S., Gulla, A., Fulciniti, M., Cleynen, A., Aktas Samur, A., & Munshi, N. C. (2018). Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia, 32(12), 2626-2635. https://doi.org/10.1038/s41375-018-0116-y
Sarasquete, M. E., Gutiérrez, N. C., Misiewicz-Krzeminska, I., Paiva, B., Chillón, M. C., Alcoceba, M., & San-Miguel, J. F. (2011). Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica, 96(3), 468-471. https://doi.org/10.3324/haematol.2010.033845
Schmitter, D., Filkowski, J., Sewer, A., Pillai, R. S., Oakeley, E. J., Zavolan, M., & Filipowicz, W. (2006). Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. Nucleic Acids Research, 34(17), 4801-4815. https://doi.org/10.1093/nar/gkl646
Shah, M. Y., Martinez-Garcia, E., Phillip, J. M., Chambliss, A. B., Popovic, R., Ezponda, T., & Licht, J. D. (2016). MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene, 35(45), 5905-5915. https://doi.org/10.1038/onc.2016.116
Shen, X., Shen, P., Yang, Q., Yin, Q., Wang, F., Cong, H., & Ju, S. (2019). Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways. Journal of Cancer, 10(26), 6502-6510. https://doi.org/10.7150/jca.35098
Shi, Y., Frost, P., Hoang, B., Benavides, A., Gera, J., & Lichtenstein, A. (2011). IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: Critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. Journal of Biological Chemistry, 286(1), 67-78. https://doi.org/10.1074/jbc.M110.153221
Stamato, M. A., Juli, G., Romeo, E., Ronchetti, D., Arbitrio, M., Caracciolo, D., & Amodio, N. (2017). Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget, 8(63), 106527-106537. https://doi.org/10.18632/oncotarget.22507
Sun, Y., Jiang, T., Jia, Y., Zou, J., Wang, X., & Gu, W. (2019). LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Cell Cycle, 18(19), 2509-2523. https://doi.org/10.1080/15384101.2019.1652034
Sun, Y., Pan, J., Zhang, N., Wei, W., Yu, S., & Ai, L. (2017). Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-kappaB pathway. Scientific Reports, 7(1):18079. https://doi.org/10.1038/s41598-017-18056-9
Taiana, E., Favasuli, V., Ronchetti, D., Todoerti, K., Pelizzoni, F., Manzoni, M., & Neri, A. (2019). Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 34, 234-244. https://doi.org/10.1038/s41375-019-0542-5.
Taiana, E., Ronchetti, D., Favasuli, V., Todoerti, K., Manzoni, M., Amodio, N., & Neri, A. (2019). Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica, 104(2), e72-e76. https://doi.org/10.3324/haematol.2018.201301
Tao, J., Zhao, X., & Tao, J. (2014). c-MYC-miRNA circuitry: A central regulator of aggressive B-cell malignancies. Cell Cycle, 13(2), 191-198. https://doi.org/10.4161/cc.27646
Tessel, M. A., Benham, A. L., Krett, N. L., Rosen, S. T., & Gunaratne, P. H. (2011). Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Hormones & Cancer, 2(3), 182-189. https://doi.org/10.1007/s12672-011-0072-8
Tucci, M., Quatraro, C., Dammacco, F., & Silvestris, F. (2009). Role of active drug transporters in refractory multiple myeloma. Current Topics in Medicinal Chemistry, 9(2), 218-224. https://doi.org/10.2174/156802609787521625
Wang, J., Hendrix, A., Hernot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., & Menu, E. (2014). Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood, 124(4), 555-566. https://doi.org/10.1182/blood-2014-03-562439
Wang, X., Li, C., Ju, S., Wang, Y., Wang, H., & Zhong, R. (2011). Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leukemia and Lymphoma, 52(10), 1991-1998. https://doi.org/10.3109/10428194.2011.591004
Wei, L. H., Kuo, M. L., Chen, C. A., Chou, C. H., Cheng, W. F., Chang, M. C., & Hsieh, C. Y. (2001). The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene, 20(41), 5799-5809. https://doi.org/10.1038/sj.onc.1204733
Wong, K. Y., Huang, X., & Chim, C. S. (2012). DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis, 33(9), 1629-1638. https://doi.org/10.1093/carcin/bgs212
Wong, K. Y., Li, Z., Zhang, X., Leung, G. K., Chan, G. C., & Chim, C. S. (2015). Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Molecular Cancer, 14, 175. https://doi.org/10.1186/s12943-015-0444-8
Wu, Y., & Wang, H. (2018). LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. Journal of Biochemical and Molecular Toxicology, 32(1):e22008. https://doi.org/10.1002/jbt.22008.
Xi, H., Li, L., Du, J., An, R., Fan, R., Lu, J., & Zhao, L. M. (2017). hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10. Oncology Reports, 37(2), 961-968. https://doi.org/10.3892/or.2016.5318
Xiao, G., Li, Y., Wang, Y., Zhao, B., Zou, Z., Hou, S., & Xiong, H. (2018). LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. Experimental Cell Research, 370(2), 254-263. https://doi.org/10.1016/j.yexcr.2018.06.026
Xiao, X., Gu, Y., Wang, G., & Chen, S. (2019). c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma. International Journal of Biological Macromolecules, 122, 526-537. https://doi.org/10.1016/j.ijbiomac.2018.10.207
Yang, X., Ye, H., He, M., Zhou, X., Sun, N., Guo, W., & Wang, H. (2018). LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. Biochemical and Biophysical Research Communications, 498(1), 207-213. https://doi.org/10.1016/j.bbrc.2018.02.211
Yang, Y., Li, F., Saha, M. N., Abdi, J., Qiu, L., & Chang, H. (2015). miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21(10), 2399-2411. https://doi.org/10.1158/1078-0432.Ccr-14-1437
Zhang, H., Chen, Z., Wang, X., Huang, Z., He, Z., & Chen, Y. (2013). Long non-coding RNA: A new player in cancer. Journal of Hematology & Oncology, 6, 37. https://doi.org/10.1186/1756-8722-6-37
Zhang, L., Pan, L., Xiang, B., Zhu, H., Wu, Y., Chen, M., & Liu, T. (2016). Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget, 7(21), 30876-30891. https://doi.org/10.18632/oncotarget.9021
Zhang, S. S., Xu, Y., Deng, S. H., Li, C. H., Zhou, W., & Qiu, L. G. (2016). Role of miR137-MITF in prognostic analysis of multiple myeloma. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = Journal of experimental hematology/Chinese Association of Pathophysiology, 24(4), 1096-1099. https://doi.org/10.7534/j.issn.1009-2137.2016.04.025
Zhang, W., Wang, Y. E., Zhang, Y., Leleu, X., Reagan, M., Zhang, Y., & Ghobrial, I. M. (2014). Global epigenetic regulation of microRNAs in multiple myeloma. PLoS One, 9(10):e110973. https://doi.org/10.1371/journal.pone.0110973
Zhang, Y., Shen, X. J., Wu, X. H., Cong, H., Ni, H. B., Ju, S. Q., & Su, J. Y. (2016). miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway. Zhonghua Xue Ye Xue Za Zhi, 37(11), 987-992. https://doi.org/10.3760/cma.j.issn.0253-2727.2016.11.012
Zhang, Y. K., Wang, H., Leng, Y., Li, Z. L., Yang, Y. F., Xiao, F. J., & Wang, L. S. (2011). Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochemical and Biophysical Research Communications, 414(1), 233-239. https://doi.org/10.1016/j.bbrc.2011.09.063
Zhao, J. J., Chu, Z. B., Hu, Y., Lin, J., Wang, Z., Jiang, M., & Carrasco, R. D. (2015). Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Research, 75(20), 4384-4397. https://doi.org/10.1158/0008-5472.Can-15-0457
Zhao, J. J., Lin, J., Zhu, D., Wang, X., Brooks, D., Chen, M., & Carrasco, R. (2014). miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Research, 74(6), 1801-1813. https://doi.org/10.1158/0008-5472.Can-13-3311-t
Zhou, F., Wang, D., Wei, W., Chen, H., Shi, H., Zhou, N., & Peng, R. (2020). Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma. BMC Cancer, 20(1), 40. https://doi.org/10.1186/s12885-020-6515-2
Zhou, Y., Chen, L., Barlogie, B., Stephens, O., Wu, X., Williams, D. R., & Shaughnessy, J. D., Jr. (2010). High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proceedings of the National Academy of Sciences of the United States of America, 107(17), 7904-7909. https://doi.org/10.1073/pnas.0908441107
Zhuang, W., Ge, X., Yang, S., Huang, M., Zhuang, W., Chen, P., & Li, B. (2015). Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription. Stem Cells, 33(6), 1985-1997. https://doi.org/10.1002/stem.1989